Condition: Transthyretin Amyloidosis With Cardiomyopathy · Sponsor: Alnylam Pharmaceuticals
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
This description comes directly from the study's public registry record.
Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | La Jolla, California, United States | Recruiting |
| Clinical Trial Site | Stanford, California, United States | Recruiting |
| Clinical Trial Site | Norwich, Connecticut, United States | Recruiting |
| Clinical Trial Site | Washington D.C., District of Columbia, United States | Recruiting |
| Clinical Trial Site | Brandon, Florida, United States | Recruiting |
| Clinical Trial Site | Miami, Florida, United States | Recruiting |
| Clinical Trial Site | Atlanta, Georgia, United States | Recruiting |
| Clinical Trial Site | Gainesville, Georgia, United States | Recruiting |
| Clinical Trial Site | Tucker, Georgia, United States | Recruiting |
| Clinical Trial Site | Evanston, Illinois, United States | Recruiting |
| Clinical Trial Site | Indianapolis, Indiana, United States | Recruiting |
| Clinical Trial Site | Indianapolis, Indiana, United States | Recruiting |
+ 228 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07052903